Definium Therapeutics (DFTX) Interest Coverage Ratio (2023 - 2026)
Definium Therapeutics (DFTX) reported Interest Coverage Ratio of 49.35 for Q1 2026, up 7.62% year-over-year from 45.86 in Q1 2025, and down 33.39% on a QoQ basis from 37.0 in Q4 2025.
Definium Therapeutics (DFTX) has 4 years of Interest Coverage Ratio data on file, last reported at 49.35 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 7.62% year-over-year to 49.35 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 31.71 (up 31.75% YoY) and the FY2025 annual result came in at 30.24, up 33.57% from the prior year.
- Interest Coverage Ratio slipped to 49.35 in Q1 2026 per DFTX's latest filing, from 37.0 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 17.49 in Q2 2025 and bottomed at 423.84 in Q3 2023.
- The 4-year median for Interest Coverage Ratio is 49.48 (2024), against an average of 114.76.
- Peak annual rise in Interest Coverage Ratio reached 91.95% in 2024, while the deepest fall reached 44.63% in 2024.
- Tracing DFTX's Interest Coverage Ratio over 4 years: stood at 34.21 in 2023, then plunged by 44.63% to 49.48 in 2024, then gained by 25.24% to 37.0 in 2025, then plunged by 33.39% to 49.35 in 2026.
- Per Business Quant, the three latest DFTX Interest Coverage Ratio figures stand at 49.35 (Q1 2026), 37.0 (Q4 2025), and 35.85 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -49.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.35 |
| Dec 31, 2025 | -37.00 |
| Sep 30, 2025 | -35.85 |
| Jun 30, 2025 | -17.49 |
| Mar 31, 2025 | -53.42 |
| Dec 31, 2024 | -49.48 |
| Sep 30, 2024 | -34.10 |
| Jun 30, 2024 | -52.48 |
| Mar 31, 2024 | -51.16 |
| Dec 31, 2023 | -34.21 |
| Sep 30, 2023 | -423.84 |
| Jun 30, 2023 | -379.01 |
| Mar 31, 2023 | -274.50 |